Obrindatamab
Based on 1 publication(s) in Google Scholar
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer.
For research use only. We do not sell to patients.
- Purity: 99.58%
- CAS No.: 2069959-72-2
- Molecular Weight:109.06 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Obrindatamab
More
Biological Activity
scFv -h-CH2-CH3(_scFv)_h-CH2-CH3
Human
CD3E & CD276
MGD009 (MGD009) binds human and cynomolgus monkey CD3 and B7-H3 with KD values of 13.9, 14.7, 24.6, and 30.2 nM for human CD3ε/δ, cynomolgus CD3ε/δ, human B7-H3-His, and cynomolgus B7-H3-His, respectively[1].
Obrindatamab (0.01-1000 ng/mL; A498, U87, 22Rv1, and Detroit562 cells) mediates redirected killing of multiple B7-H3-expressing tumor lines[1].
Obrindatamab (0.01-1000 ng/mL; PBMCs and A498 cells) mediated T-cell activation and proliferation is target antigen dependent[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID mice with Co-mix mouse xenograft model, Established tumor model in human T-cell reconstituted NSG b2m-/- mice, Established tumor model in human T-cell reconstituted MHC1-/- mice[1]
-
Dosage:0.004-1 mg/kg
-
Administration:intravenous injection
-
Result:Had antitumor activity in multiple in vivo models.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
scFv-h-CH2-CH3(_scFv)_h-CH2-CH3
ELISA, FACS, Functional assay
-
Immobilized Obrindatamab can bind Human CD3 epsilon/CD3e Protein (ECD, His Tag). The EC50 for this effect is 0.543 ng/mL. -
Immobilized Obrindatamab can bind Human B7-H3 Protein (ECD, His Tag). The EC50 for this effect is 3.27 ng/mL. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Obrindatamab (HY-P99762). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2069959-72-2
-
Appearance Liquid
-
Molecular Weight 109.06 kDa
-
Color Colorless to light yellow
-
SMILES
[Obrindatamab]
-
Synonyms
MGD009
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Reprogramming the Tumor Immune Microenvironment with ICAM-1-Targeted Antibody‒Drug Conjugates and B7-H3-CD3 Bispecific Antibodies. [Abstract]2025 Apr;12(16):e2415577. PMID: 39996528
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)